1-17 of 17
Jason Melear
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1a/b Trial of Luxeptinib (CG-806) in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia and Evaluation of New G3 Formulation

Aaron D. Goldberg, Felipe Samaniego, Maro Ohanian, Paul B. Koller, Namrata Sonia Chandhok, Ahad A. Sadiq, Daruka Mahadevan, Mohamad A. Cherry, Jessica K. Altman, John M. Burke, Michael Z. Koontz, J. C. C Villasboas, Ben K. Tomlinson, Laura E. Finn, Erin G Reid, Jason Melear, Victor Priego, Patrick Cobb, Elizabeth Heritage Cull, Paul Conkling, David Cosgrove, Lindsey E. Roeker, Eric Tam, Donna Nguyen Haney, Jia Hu, Ranjeet Sinha, Nawazish Khan, William G. Rice, Rafael Bejar
Journal: Blood
Blood (2023) 142 (Supplement 1): 5953.
https://doi.org/10.1182/blood-2023-181151
Published: 2023
Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced Stage Classical Hodgkin Lymphoma: Efficacy and Safety Results from the Single Arm Phase 2 Study

Hun Ju Lee, Ian W. Flinn, Jason Melear, Rod Ramchandren, Judah Friedman, John M. Burke, Yuliya Linhares, Paul Alan Gonzales, Mihir Raval, Rangaswamy Chintapatla, Tatyana Feldman, Habte A. Yimer, Miguel Islas-Ohlmayer, Asad Dean, Vishal Rana, Mitul Gandhi, John Scott Renshaw, Linda Ho, Michelle A. Fanale, Wenchuan Guo, Chris Yasenchak
Journal: Blood
Blood (2023) 142 (Supplement 1): 608.
https://doi.org/10.1182/blood-2023-173972
Published: 2023
Journal Articles

A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies

Felipe Samaniego, Ahad A. Sadiq, Daruka Mahadevan, Michael Z. Koontz, Jose C. Villasboas, John M. Burke, Erin G Reid, Mohamad Cherry, Jason Melear, Victor Priego, Patrick Cobb, Elizabeth H. Cull, Paul Conkling, David Cosgrove, Lindsey E. Roeker, Donna Nguyen Haney, Jia Hu, Ranjeet Kumar Sinha, William G Rice, Rafael Bejar
Journal: Blood
Blood (2022) 140 (Supplement 1): 6498–6500.
https://doi.org/10.1182/blood-2022-163683
Published: 2022
Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Updated Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B)

Hun Lee, Ian W. Flinn, Jason Melear, Rod Ramchandren, Judah Friedman, John M. Burke, Yuliya Linhares, Paul Alan Gonzales, Mihir Raval, Rangaswamy Chintapatla, Tatyana Feldman, Habte Yimer, Miguel Islas-Ohlmayer, Asad Dean, Vishal Rana, Mitul Gandhi, John Renshaw, Linda Ho, Michelle A. Fanale, Wenchuan Guo, Christopher A. Yasenchak
Journal: Blood
Blood (2022) 140 (Supplement 1): 763–765.
https://doi.org/10.1182/blood-2022-156553
Published: 2022
Journal Articles

Sea-BCMA Mono- and Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study (SGNBCMA-001)

James E. Hoffman, Brea Lipe, Jason Melear, Michaela Liedtke, Mark A. Schroeder, Ruben Niesvizky, Christopher Strouse, Christopher A. Yasenchak, Damian J. Green, Jeremy Sauer, Yinghui Wang, Phoenix Ho, Al-Ola Abdallah
Journal: Blood
Blood (2022) 140 (Supplement 1): 10160–10162.
https://doi.org/10.1182/blood-2022-157347
Published: 2022
Journal Articles

Treatment Initiation of Venetoclax in Combination with Azacitidine or Decitabine in an Outpatient Setting in Patients with Untreated Acute Myeloid Leukemia

Sudhir Manda, Bertrand Anz, III, Christopher Benton, E. Randolph Broun, Habte Yimer, John Renshaw, George F. Geils, Jr., Jose Cruz, Suzanne Fanning, Jason Melear, Jeff P. Sharman, Kingston Kang, Anders Svensson, Madhavi Pai, William Donnellan
Journal: Blood
Blood (2021) 138 (Supplement 1): 1265.
https://doi.org/10.1182/blood-2021-144886
Published: 2021
Journal Articles

SEA-BCMA, an Investigational Nonfucosylated Monoclonal Antibody: Ongoing Results of a Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma (SGNBCMA-001)

James E Hoffman, Brea Lipe, Jason Melear, Michaela Liedtke, Mark A. Schroeder, Ruben Niesvizky, Michael H. Tomasson, Christopher A. Yasenchak, Damian J. Green, Hong Li, Yinghui Wang, Phoenix Ho, Al-Ola Abdallah
Journal: Blood
Blood (2021) 138 (Supplement 1): 2740.
https://doi.org/10.1182/blood-2021-146047
Published: 2021
Journal Articles

Efficacy and Safety of Umbralisib, Ublituximab (U2), and U2 Plus Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

John M. Burke, Gustavo Fonseca, Wojciech Jurczak, Jason Melear, Miguel Islas-Ohlmayer, James A Reeves, Parameswaran Venugopal, Tomasz Wróbel, Don Stevens, John M. Pagel, Jerome Goldschmidt, Hari P. Miskin, Peter Sportelli, Owen A. O'Connor, Nilanjan Ghosh
Journal: Blood
Blood (2021) 138 (Supplement 1): 527.
https://doi.org/10.1182/blood-2021-151054
Published: 2021
Journal Articles

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Preliminary Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B)

Hun Ju Lee, Ian W. Flinn, Jason Melear, Rod Ramchandren, Judah Friedman, John M. Burke, Yuliya Linhares, Matthew R. Peterson, Mihir Raval, Rangaswamy Chintapatla, Tatyana A. Feldman, Habte Yimer, Miguel Islas-Ohlmayer, Asad Dean, Vishal Rana, Mitul D. Gandhi, John Renshaw, Amanda L. Gillespie-Twardy, Linda Ho, Michelle A. Fanale, Wenchuan Guo, Christopher A. Yasenchak
Journal: Blood
Blood (2021) 138 (Supplement 1): 2454.
https://doi.org/10.1182/blood-2021-147891
Published: 2021
Journal Articles

Completed Induction Phase Analysis of Magnify: Phase 3b Study of Lenalidomide + Rituximab (R 2 ) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Frederick Lansigan, David Jacob Andorsky, Morton Coleman, Abdulraheem Yacoub, Jason Melear, Suzanne Fanning, Kathryn S. Kolibaba, Christopher M. Reynolds, Grzegorz S. Nowakowski, Mecide Gharibo, Jung Ryun Ahn, Ju Li, Mathias J. Rummel, Jeff P. Sharman
Journal: Blood
Blood (2021) 138 (Supplement 1): 812.
https://doi.org/10.1182/blood-2021-145640
Published: 2021
Journal Articles

Phase 1/2 Study of Oral TP-0184 for the Treatment of Anemia in Adults with Low- or Intermediate-Risk Myelodysplastic Syndromes

Amit Verma, Andrew M. Brunner, Gregory Pennock, Dragana McMullen, Mark Wade, Huyuan Yang, Yuran Xie, Cliff Whatcott, Jason Foulks, Jason Melear
Journal: Blood
Blood (2021) 138 (Supplement 1): 1534.
https://doi.org/10.1182/blood-2021-147594
Published: 2021
Journal Articles

Debulking before Initiation of Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Results from a Phase 3b Study

Ian W. Flinn, David Andorsky, Jason Melear, Sudhir Manda, Bertrand Anz, III, Kathryn Kolibaba, Habte Yimer, John M. Burke, Suzanne Fanning, Jay Courtright, Miguel Islas-Ohlmayer, Suman Kambhampati, Tamas Vizkelety, John Pesko, Brenda Chyla, Dingfeng Jiang, Jeff P. Sharman
Journal: Blood
Blood (2021) 138 (Supplement 1): 3725.
https://doi.org/10.1182/blood-2021-147258
Published: 2021
Journal Articles

A Phase 1a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory B-Cell Malignancies

Felipe Samaniego, John M. Burke, Daruka Mahadevan, Mohamad Cherry, Ahad A. Sadiq, M. Zach Koontz, Jose C. Villasboas, Erin Reid, Elizabeth Cull, Victor Priego, Lindsey E. Roeker, Patrick Cobb, Jason Melear, Paul Conkling, David Cosgrove, Hongying Zhang, Nasrin Rastgoo, Khalid Benbatoul, Donna Nguyen Haney, Yuying Jin, Jotin Marango, Stephen B Howell, William G Rice, Rafael Bejar
Journal: Blood
Blood (2021) 138 (Supplement 1): 1355.
https://doi.org/10.1182/blood-2021-148827
Published: 2021
Journal Articles

Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM)

Habte Yimer, MD, Jason Melear, MD, Edward Faber, DO, MS, William Bensinger, MD, John M Burke, Mohit Narang, MD, Don Stevens, MD, Sriya W. Gunawardena, MD, Yana Lutska, PharmD, Keqin Qi, PhD, Jon Ukropec, PhD, Ming Qi, MD PhD, Thomas Lin, MD PhD, Robert M Rifkin, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 152.
https://doi.org/10.1182/blood-2018-152
Published: 2018
Journal Articles

Results of an Interim Safety Analysis of a Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Previously Untreated and Relapsed Patients (Pts) with Multiple Myeloma (MM)

Habte Yimer, MD, Jason Melear, MD, Edward Faber, William I. Bensinger, MD, John M Burke, MD, Sriya Gunawardena, MD, Murphy Sean, Hollee Parros, Yana Lutska, Mohamed Darif, PhD, Anil Londhe, PhD, Ming Qi, Jon Ukropec, Thomas Lin, Robert M. Rifkin, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1839.
https://doi.org/10.1182/blood.V130.Suppl_1.1839.1839
Published: 2017
Journal Articles

MAGNIFY: Phase IIIb Randomized Study of Lenalidomide Plus Rituximab (R 2 ) Followed By Lenalidomide Vs. Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma

David J. Andorsky, MD, Abdulraheem Yacoub, MD, Jacob D. Bitran, MD, Jason Melear, MD, Heather D. Brooks, MD BS, BA, Kenneth A. Foon, MD, Syed Rizvi, MD, Mary Llorente, Jiahui Li, PhD, Jeff P. Sharman, MD
Journal: Blood
Blood (2016) 128 (22): 1798.
https://doi.org/10.1182/blood.V128.22.1798.1798
Published: 2016
Journal Articles

Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma; Results of a Phase II Trial

Kathryn Kolibaba, MD, John M. Burke, MD, Heather D. Brooks, MD BS, BA, Daruka Mahadevan, MD PhD, Jason Melear, MD, Charles M. Farber, MD PhD, Suzanne R. Fanning, DO, Marshall T. Schreeder, MD, Ralph V. Boccia, MD, Peter Sportelli, Hari P. Miskin, MS, Michael S. Weiss, Jeff P. Sharman, MD
Journal: Blood
Blood (2015) 126 (23): 3980.
https://doi.org/10.1182/blood.V126.23.3980.3980
Published: 2015